Improving Glycaemic Outcomes in Uncontrolled High Risk Type 2 Diabetes

The practicalities of using Suliqua®▼(insulin glargine 100 units/mL and lixisenatide) – why now?

An hour long interactive webinar
5th May 2021 | 1-2pm or 7-8pm

Join us for an hour long, interactive live webinar on 5 May 2021 at either 1 or 7 PM. The event is hosted by Ed Jude, Consultant in Diabetes and Endocrinology, Tameside Hospital NHS Foundation Trust and Grace Vanterpool, Nurse Consultant – Diabetes, West London NHS Trust.

Ed and Grace will explore the role of Suliqua in addressing the challenges facing people with uncontrolled type 2 diabetes currently on two or more OADs. The practicalities of initiating Suliqua in this patient population will also be discussed.

Throughout the webinar you will have the opportunity to submit your questions for a live question and answer session with the speakers immediately after the broadcast.


Time Session SPEAKER
5 minutes  Introduction and Welcome
Setting the scene:
The current state of the nation and the reality facing people with uncontrolled Type 2 diabetes
NICE recommendations for people with uncontrolled Type 2 Diabetes with an HbA 275 mmol/mol [9%] currently on OADs
The rationale for using the fixed ratio combination Suliqua (insulin glargine 100 units/mL and lixisenatide)
Ed Jude
 10 minutes Intensification to premixed insulin: What are the challenges?
Balancing the need to achieve glycaemic control vs increased risk of weight gain and hypoglycaemia associated with premixed insulin
Real-world data illustrating the low probability of achieving glycaemic targets with premixed insulin
Ed Jude
10 minutes The role of Suliqua in addressing unmet needs 
Summary of key findings from Phase III trials
Comparing Suliqua with other approaches: Results from a recent network meta-analysis
Ed Jude
15 minutes Initiation of Suliqua in people with uncontrolled Type 2 diabetes on OADs: A practical guide
Introducing Suliqua and licensed indications
Which patients are suited to Suliqua?
Initiation and titration of Suliqua
Monitoring patients in a virtual setting
Grace Vanterpool
20 minutes Live Q&A Session Grace Vanterpool and Ed Jude


CPD credits have been applied for this webinar. This promotional webinar is organised and funded by Sanofi. This event is intended for UK healthcare professionals only. Adverse events reporting and prescribing information will be available at the meeting. Please note that to be eligible for CPD point, you will need to attend a minimum of 1 hour of the live event.


Grace Vanterpool

Grace Vanterpool

Nurse Consultant, Diabetes, West London
NHS Trust

Ed Jude

Ed Jude

Consultant in Diabetes and Endocrinology
Tameside Hospital NHS Foundation Trust

This site uses cookies to store information on your computer. Some cookies on this site are needed because the site won’t work as expected without them. To learn more about cookies, please read our Cookie Policy.
By closing this message or using the website, you agree to our use of cookies on this device in agreement with our Cookie Policy, unless you have turned them off.
Accept and close